Mauprivez Cédric, Khonsari Roman Hossein, Razouk Omar, Goudot Patrick, Lesclous Philippe, Descroix Vianney
AP-HP, Service d'Odontologie, Groupe Hospitalier Pitié Salpêtrière Charles Foix, Paris, France; Service d'Odontologie, Hôpital Maison Blanche, Centre Hospitalier Universitaire, Reims, France; Laboratoire E.A., 4691 Biomateriaux et Inflammation en Site Osseux, Université Reims Champagne-Ardennes, Reims, France.
AP-HP, Service de chirurgie maxillo-faciale, Paris, France; UPMC Université Paris 06, Paris, France.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Nov;122(5):e146-e155. doi: 10.1016/j.oooo.2016.06.003. Epub 2016 Jun 22.
The main goal of this study was to compare the incidence of postoperative bleeding events after dental extractions between patients treated with direct oral anticoagulants (DOACs) and those treated with vitamin K antagonists (VKAs) without withdrawal of oral anticoagulant therapy (OAT). Our second objective was to evaluate the risk factors affecting postoperative hemorrhage after tooth extraction in patients taking DOACs.
This prospective observational study included 51 patients who were being treated with oral anticoagulants and required dental extractions. They were divided into two groups: 31 patients receiving a DOAC and 20 control patients taking VKA with an international normalized ratio between 2.0 and 3.0. In both groups, extractions were performed under continued OAT, and the same local hemostatic measures were applied. All procedures were performed in an outpatient facility. A bleeding event was defined as persistent oozing or marked hemorrhage over 20 minutes after tooth extraction despite local hemostasis procedures or all bleeding episode occurring during the first postoperative week.
Five patients taking DOACs had seven bleeding episodes, and four patients receiving VKAs had five bleeding episodes during the postoperative follow-up period. The difference in the number of bleeding events between the two groups was not statistically significant (adjusted odds ratio = 0.77; 95% confidence interval 0.19-3.19; P = .723). Eleven (91.67%) bleeding events were mild and controlled by mechanical compression with gauzes, and one (8.33 %) was managed with a revision of the wound, application of fibrin glue, and resuturing. No bleeding required hospitalization or blood transfusion. All bleeding episodes occurred during the first 3 postoperative days.
According to our preliminary outcome data, dental extractions can be performed safely in an outpatient facility in patients treated with DOAC by applying local hemostatic measures, without interrupting or modifying OAT.
本研究的主要目的是比较直接口服抗凝剂(DOACs)治疗的患者与维生素K拮抗剂(VKAs)治疗且未停用口服抗凝治疗(OAT)的患者拔牙术后出血事件的发生率。我们的第二个目的是评估影响服用DOACs的患者拔牙术后出血的危险因素。
这项前瞻性观察性研究纳入了51例正在接受口服抗凝治疗且需要拔牙的患者。他们被分为两组:31例接受DOAC治疗的患者和20例接受VKA治疗且国际标准化比值在2.0至3.0之间的对照患者。两组均在持续OAT下进行拔牙,并采用相同的局部止血措施。所有手术均在门诊进行。出血事件定义为拔牙后尽管采取了局部止血措施仍持续渗血或20分钟以上的明显出血,或术后第一周内发生的所有出血情况。
在术后随访期间,5例服用DOACs的患者发生了7次出血事件,4例接受VKA治疗的患者发生了5次出血事件。两组出血事件数量的差异无统计学意义(调整后的优势比=0.77;95%置信区间0.19 - 3.19;P = 0.723)。11次(91.67%)出血事件为轻度,通过用纱布机械压迫得以控制,1次(8.33%)通过伤口清创、应用纤维蛋白胶和再次缝合处理。无需住院或输血治疗。所有出血事件均发生在术后前3天。
根据我们的初步结果数据,对于接受DOAC治疗的患者,在门诊通过采取局部止血措施可以安全地进行拔牙,而无需中断或调整OAT。